Mounjaro®
Starting from £179.99/mo
Start journey Learn moreSkin itching is reported by some people taking Wegovy (semaglutide), and it appears in the medicine's clinical data, though it is not among the most common reactions. The Wegovy SmPC and NHS patient information for semaglutide list injection-site reactions, including localised redness and irritation, as known effects; a broader, non-site-specific itch is less frequent but documented. Because semaglutide is a prescription-only medicine, any skin reaction worth noting during treatment should be discussed with the prescriber who oversees your care — they can weigh it against your full clinical picture.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
The STEP 1 trial (published in the New England Journal of Medicine and involving nearly 2,000 adults with obesity) recorded gastrointestinal effects as the dominant side-effect profile for semaglutide 2.4mg. Skin reactions were not among the headline findings, but they surfaced in the safety data, as they do in the broader product labelling.
The Wegovy SmPC categorises injection-site reactions, including localised pruritus (itch at the needle site), as common, meaning they occur in more than one in every hundred users. Generalised pruritus, where the itch is not confined to where the pen was used, is listed as uncommon, putting it somewhere between one in a hundred and one in a thousand users. Neither figure means the reaction is severe; it means it has been observed consistently enough to warrant mention in the label.
The practical takeaway: if you notice itching after starting Wegovy, a small, itchy patch forming where you injected is one of the more predictable responses to a subcutaneous injection and usually settles within hours. If the itch is spreading well beyond the site, or arriving days after the injection, that deserves a conversation with your prescriber.
A question our prescribers field regularly is whether the itch is from the medicine itself or from how it is administered. Both can contribute. Semaglutide is injected subcutaneously, into the fat layer beneath the skin of the abdomen, thigh, or upper arm. Injecting repeatedly into exactly the same spot can cause localised irritation, a small lump called a lipohypertrophy, and persistent itch or sensitivity at that area.
Rotating your injection site each week (moving around the abdomen, alternating thighs, or using the upper arm) gives skin time to recover between doses. The semaglutide information on our treatment pages covers the broader administration points, and the patient information leaflet inside your pen box gives the precise rotation guidance. One quick habit that takes under a minute: before you inject, press lightly on the area you used last week; if it still feels tender or raised, choose a different spot on the opposite side.
Keeping the injection pen at room temperature for a few minutes before use can also reduce the sting and subsequent skin itchiness that some Wegovy users report, the leaflet specifies the maximum time out of the fridge, so always check that.
Mild, localised itch is one thing. There are patterns that should not be waited out. The MHRA Yellow Card scheme captures reports of suspected side effects from medicines including Wegovy, and allergic reactions are among the reasons it exists.
If itching comes alongside hives (raised, blotchy welts anywhere on the body), swelling of the lips, tongue or face, dizziness, or difficulty breathing, stop the injection and call 999 or go to A&E. That combination points toward a serious allergic response rather than a routine skin reaction. It is rare, but it moves quickly.
More broadly, any skin change that is worsening rather than settling, or that appears for the first time after a dose increase, is worth raising with a prescriber before your next pen. Dose escalation changes the amount of semaglutide your body is processing, and some reactions appear or intensify at higher doses. Patients sometimes ask whether semaglutide itself is responsible for the itching they experience, and if you have questions about a reaction you are experiencing and you are a patient with us, our aftercare team is available seven days a week to help you decide whether something needs escalating.
For the majority of people using Wegovy, the side effects that dominate the early weeks are gastrointestinal: nausea, loose stools, and a general unsettled stomach as the dose climbs. Skin reactions, where they occur, are typically less disruptive. That said, everyone's immune profile is different, and it is worth understanding whether semaglutide can cause itchy skin before dismissing a change just because it is less common than nausea.
If you are weighing up whether Wegovy is right for you, or trying to understand what to expect at each stage of treatment, our Wegovy overview covers the full clinical picture from licence to how it is taken. A prescriber will discuss your personal health history before any treatment begins, including any previous skin or allergy history that might be relevant, and this includes reviewing how Wegovy may affect your skin given your individual profile. The broader weight-loss treatment options are also worth reviewing if you want to compare what is available before making a decision.
Wegovy is a prescription-only medicine. Starting a free consultation with our clinical team is the way to get answers that are specific to you, rather than to averages. If it is clinically appropriate, you can begin that process here.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.